×
About 24,190 results

ALLMedicine™ Hypoglycemia Center

Research & Reviews  10,959 results

Impacts of early insulin treatment vs glimepiride in diabetic patients with background ...
https://doi.org/10.1097/MD.0000000000025085
Medicine Yen FS, Hsu CC et. al.

Mar 3rd, 2021 - Type 2 diabetes mellitus (T2DM) is a progressive disease. After metformin failure, the addition of insulin or sulfonylureas might increase the risk of hypoglycemia and cardiovascular (CV) morbidity. Here, the risk of all-cause mortality was compar...

Self-Management Group Education to Reduce Fear of Hypoglycemia as a Barrier to Physical...
https://doi.org/10.1016/j.jcjd.2021.01.001
Canadian Journal of Diabetes; Brennan MC, Albrecht MA et. al.

Mar 2nd, 2021 - The aim of this study was to evaluate the feasibility, acceptability and preliminary efficacy of a theory-driven group education intervention designed to reduce fear of hypoglycemia (FoH) as a barrier to physical activity (PA) in adults with type ...

Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn...
https://doi.org/10.1001/jamainternmed.2020.9176
JAMA Internal Medicine; Bradley MC, Chillarige Y et. al.

Mar 1st, 2021 - Previous studies have found that the risk of severe hypoglycemia does not differ between long-acting insulin analogs and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes. However, these studies did not focus on patients 65...

In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or...
https://doi.org/10.7326/ACPJ202103160-034
Annals of Internal Medicine; Griffin TP, Dinneen SF

Mar 1st, 2021 - Rosenstock J, Bajaj HS, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020:383:2107-16. 32960514.

Comparison of two carbohydrate intake strategies to improve glucose control during exer...
https://doi.org/10.1016/j.numecd.2020.12.011
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Goulet-Gélinas L, Saade MB et. al.

Feb 26th, 2021 - During aerobic physical activity (PA), hypoglycemia is common in people with type 1 diabetes (T1D). Few studies have compared the effectiveness of different carbohydrate (CHO) intake strategies to prevent PA-induced hypoglycemia. Our objective was...

see more →

Guidelines  49 results

Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.
https://doi.org/10.1210/clinem/dgaa543
The Journal of Clinical Endocrinology and Metabolism; Brar PC, Heksch R et. al.

Aug 18th, 2020 - The diagnosis of hypoglycemia and the use of diazoxide have risen in the last decade. Diazoxide is the only Food and Drug Agency-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). Recent publications have hi...

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
The New England Journal of Medicine; McMurray,J.,et al

Sep 18th, 2019 - BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the eff...

Xeris Pharmaceuticals Receives U.S. Fda Approval For Gvoke™ (Glucagon), The First Ready-to-use Stable Liquid Glucagon For Severe Hypoglycemia
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

Sep 9th, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received reg...

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally

Jul 23rd, 2019 - The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. BAQSIMI i...

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
http://care.diabetesjournals.org/content/42/6/1147
Diabetes Care; Danne,T.,et al

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia...

see more →

Drugs  91 results see all →

Clinicaltrials.gov  11,835 results

Impacts of early insulin treatment vs glimepiride in diabetic patients with background ...
https://doi.org/10.1097/MD.0000000000025085
Medicine Yen FS, Hsu CC et. al.

Mar 3rd, 2021 - Type 2 diabetes mellitus (T2DM) is a progressive disease. After metformin failure, the addition of insulin or sulfonylureas might increase the risk of hypoglycemia and cardiovascular (CV) morbidity. Here, the risk of all-cause mortality was compar...

Self-Management Group Education to Reduce Fear of Hypoglycemia as a Barrier to Physical...
https://doi.org/10.1016/j.jcjd.2021.01.001
Canadian Journal of Diabetes; Brennan MC, Albrecht MA et. al.

Mar 2nd, 2021 - The aim of this study was to evaluate the feasibility, acceptability and preliminary efficacy of a theory-driven group education intervention designed to reduce fear of hypoglycemia (FoH) as a barrier to physical activity (PA) in adults with type ...

Nursing Home Residents at Risk for Overtreatment of Diabetes
https://www.medscape.com/viewarticle/946666

Mar 1st, 2021 - (Reuters Health) - Many nursing home residents with diabetes may be treated to intensive glycemic targets even though such aggressive management may have limited benefit, a new study suggests. Researchers examined data on 15,034 adults with diabet...

Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn...
https://doi.org/10.1001/jamainternmed.2020.9176
JAMA Internal Medicine; Bradley MC, Chillarige Y et. al.

Mar 1st, 2021 - Previous studies have found that the risk of severe hypoglycemia does not differ between long-acting insulin analogs and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes. However, these studies did not focus on patients 65...

Less Risk of Severe Hypoglycemia With Long-Acting Insulin Analogs in Elderly
https://www.medscape.com/viewarticle/946662

Mar 1st, 2021 - NEW YORK (Reuters Health) - Long-acting insulin analogs may be a safer option than neutral protamine Hagedorn (NPH, also known as isophane insulin) in elderly patients with type 2 diabetes initiating insulin therapy, according to a large observati...

see more →

News  1,209 results

Nursing Home Residents at Risk for Overtreatment of Diabetes
https://www.medscape.com/viewarticle/946666

Mar 1st, 2021 - (Reuters Health) - Many nursing home residents with diabetes may be treated to intensive glycemic targets even though such aggressive management may have limited benefit, a new study suggests. Researchers examined data on 15,034 adults with diabet...

Less Risk of Severe Hypoglycemia With Long-Acting Insulin Analogs in Elderly
https://www.medscape.com/viewarticle/946662

Mar 1st, 2021 - NEW YORK (Reuters Health) - Long-acting insulin analogs may be a safer option than neutral protamine Hagedorn (NPH, also known as isophane insulin) in elderly patients with type 2 diabetes initiating insulin therapy, according to a large observati...

Continuous Glucose Monitoring Curbs Hyperglycemia, Hypoglycemia in Preemies
https://www.medscape.com/viewarticle/946348

Feb 24th, 2021 - NEW YORK (Reuters Health) - In preterm infants, continuous glucose monitoring (CGM) reduced prolonged or severe hyperglycemia and hypoglycemia in an international randomized controlled trial. Both conditions "are associated with long-term harm," D...

High Glucose in Kids With Type 1 Diabetes 'Noxious to the Brain'
https://www.medscape.com/viewarticle/946379

Feb 23rd, 2021 - Type 1 diabetes appears to affect cognitive development in young children, with adverse effects persisting over time, and with strong associations with long- and short-term hyperglycemia, a new longitudinal study shows. "[The results show] the bra...

FDA OKs First Generic Injected Glucagon for Hypoglycemia
https://www.medscape.com/viewarticle/943385

Dec 29th, 2020 - The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA determined that Amphastar Pharmaceuticals' Glucagon ...

see more →

Patient Education  47 results see all →